Gland Pharma Ltd

Gland Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 1852, up 2.88% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.5% on the day, quoting at 25293. The Sensex is at 82170.1, down 0.48%. Gland Pharma Ltd has added around 7.55% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has added around 4.67% in last one month and is currently quoting at 21564, up 0.46% on the day. The volume in the stock stood at 3.46 lakh shares today, compared to the daily average of 2.85 lakh shares in last one month.The PE of the stock is 24.98 based on TTM earnings ending December 25.Powered by Capital Market - Live

Five-Star Business Finance Ltd, ABB India Ltd, Gillette India Ltd, Star Health & Allied Insurance Company Ltd are among the other stocks to see a surge in volumes on NSE today, 29 January 2026.Gland Pharma Ltd registered volume of 27.34 lakh shares by 14:14 IST on NSE, a 28.57 fold spurt over two-week average daily volume of 95695 shares. The stock rose 7.13% to Rs.1,810.10. Volumes stood at 2.33 lakh shares in the last session.Five-Star Business Finance Ltd registered volume of 90.56 lakh shares by 14:14 IST on NSE, a 13.19 fold spurt over two-week average daily volume of 6.87 lakh shares. The stock slipped 11.38% to Rs.444.25. Volumes stood at 8.98 lakh shares in the last session.ABB India Ltd notched up volume of 21.89 lakh shares by 14:14 IST on NSE, a 8.56 fold spurt over two-week average daily volume of 2.56 lakh shares. The stock rose 9.37% to Rs.5,516.00. Volumes stood at 4.19 lakh shares in the last session.Gillette India Ltd saw volume of 1.54 lakh shares by 14:14 IST on NSE, a 7.39 fold spurt over two-week average daily volume of 20794 shares. The stock increased 4.51% to Rs.8,223.00. Volumes stood at 16644 shares in the last session.Star Health & Allied Insurance Company Ltd witnessed volume of 27.23 lakh shares by 14:14 IST on NSE, a 6.59 times surge over two-week average daily volume of 4.13 lakh shares. The stock increased 2.28% to Rs.450.60. Volumes stood at 7.53 lakh shares in the last session.Powered by Capital Market - Live

Revenue from USA aggregated to Rs 868.5 crore (up 19% YoY), Europe revenue added up to Rs 4,071 crore (up 54% YoY) and that from Rest of the world was Rs 300 crore (up 4% YoY). Sales in Canada, Australia and New Zealand were Rs 45.4 crore (down 1% YoY) and those in India were Rs 74.4 crore (up 32% YoY). PBIDT improved by 13.2% to Rs 473.70 crore in Q3 FY26 from Rs 418.45 crore in Q3 FY25. Profit before tax stood at Rs 362.13 crore in Q3 FY26, up by 21.0% from Rs 299.30 crore recorded in Q3 FY25. Quarterly R&D investments increased to Rs 65 crore as against Rs 43.7 crore in the previous year. Srinivas Sadu, executive chairman of Gland Pharma, stated, 'Our strong Q3 FY26 performance, driven by robust year-on-year revenue growth of 22% and healthy adj. EBITDA margin of 26%, reflects the disciplined execution across our businesses. We remain confident in sustaining this momentum as new product launches, CDMO contract ramp ups, and operational efficiencies continue to strengthen our trajectory.' Shyamakant Giri, chief executive officer of Gland Pharma, said: 'Performance of Q3 FY26 was a clear reflection of consistent execution, with double-digit growth across key markets, of US and Europe, and steady improvement in margins. Cenexi's breakeven and strong revenue traction in the base business were key contributors to our consolidated performance this quarter.' Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small-volume liquid parenteral products to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets.Powered by Capital Market - Live

Net profit of Gland Pharma rose 27.74% to Rs 261.48 crore in the quarter ended December 2025 as against Rs 204.69 crore during the previous quarter ended December 2024. Sales rose 22.49% to Rs 1695.36 crore in the quarter ended December 2025 as against Rs 1384.05 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales1695.361384.05 22 OPM %25.6526.01 - PBDT494.12395.63 25 PBT386.48299.30 29 NP261.48204.69 28 Powered by Capital Market - Live

Gland Pharma will hold a meeting of the Board of Directors of the Company on 28 January 2026.Powered by Capital Market - Live

The said drug is therapeutically equivalent to the reference listed drug (RLD), Pataday Once Daily Relief, 0.7%, of Alcon Laboratories Inc (Alcon). The said drug indicated for the treatment of ocular itching associated with allergic conjunctivitis. Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India. The company's consolidated net profit increased 12.3% to Rs 183.68 crore on 5.8% rise in net sales to Rs 1486.88 crore in Q2 FY26 over Q2 FY25.Powered by Capital Market - Live

Securities in F&O Ban: Shares of Steel Authority of India(SAIL) and Sammaan Capital are banned from F&O trading on 8 January 2026. Stocks to Watch: Gland Pharma has received an approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) filed for Olopatadine Hydrochloride Ophthalmic Solution. The said drug is indicated for the treatment of ocular itching associated with allergic conjunctivitis. Angel One is scheduled to meet on Thursday, 15 January, 2026 to consider sub-division/split of existing equity shares having face value of Rs 10 each, fully paid up. Tata Steel's India crude steel production stood at 6.34 million tons in Q3 FY26, up 12% QoQ and YoY, primarily aided by higher output at Jamshedpur and Kalinganagar facilities. Meesho's general manager- business, Megha Agarwal has tendered her resignation with effect from 7 January 2026. Following her exit, Milan Partani, General Manager - User Growth and Content Commerce will now assume the role of General Manager ' Commerce Platform. Swaraj Engines received a warning letter from BSE and National Stock Exchange of India (NSE) for non-compliance with Regulation 21 (3A) of SEBI Listing Regulations, wherein only one meeting of the Risk Management Committee was held during the financial year 2024-25. Housing & Urban Development Corporation (HUDCO) has signed a non-binding MoU with the Chhattisgarh government to provide financial assistance of up to Rs 1 lakh crore over five years for housing and infrastructure projects.Powered by Capital Market - Live

Net profit of Gland Pharma rose 12.32% to Rs 183.68 crore in the quarter ended September 2025 as against Rs 163.53 crore during the previous quarter ended September 2024. Sales rose 5.77% to Rs 1486.88 crore in the quarter ended September 2025 as against Rs 1405.83 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales1486.881405.83 6 OPM %21.1121.13 - PBDT390.23350.60 11 PBT283.92256.78 11 NP183.68163.53 12 Powered by Capital Market - Live

Gland Pharma will hold a meeting of the Board of Directors of the Company on 3 November 2025.Powered by Capital Market - Live

Gland Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 1915.3, up 1.55% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.43% on the day, quoting at 24628.25. The Sensex is at 80338.6, down 0.47%. Gland Pharma Ltd has dropped around 2.16% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has dropped around 1.55% in last one month and is currently quoting at 21915.4, down 0.26% on the day. The volume in the stock stood at 1.1 lakh shares today, compared to the daily average of 2.57 lakh shares in last one month.The PE of the stock is 27.37 based on TTM earnings ending June 25.Powered by Capital Market - Live